Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for ...

Re-treatment with ligelizumab is effective and generally well tolerated in patients with chronic spontaneous urticaria who ...

Key updates on urticaria from the American College of Allergy, Asthma & Immunology (ACAAI) include new data on dupilumab for chronic urticaria, relative effectiveness and side effects of 55 ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Despite H1-antihistamine strategies, 89% of patients with CSU experience uncontrolled symptoms, indicating a need for more effective treatments. The survey revealed high rates of comorbidities, with ...

Patients with chronic spontaneous urticaria (CSU) often experience impaired QOL, especially when antihistamines, the standard ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

In September 2025, the US Food and Drug Administration (FDA) approved Rhapsido ® (remibrutinib), an oral small molecule kinase inhibitor, for the treatment of chronic spontaneous urticaria (CSU) in ...

Patients with chronic spontaneous urticaria experienced relief in itch and hives by day 3 with povorcitinib, according to ...

The FDA has approved Quzyttir for the treatment of acute urticaria in adults and children 6 months of age and older. The Food and Drug Administration (FDA) has approved Quzyttir (cetirizine ...

Please provide your email address to receive an email when new articles are posted on . Patients remained symptomatic despite H1 antihistamine care and had not tried omalizumab. 30.6% of the treatment ...

Living with chronic spontaneous urticaria (CSU) can mean having many uncomfortable days. Worse yet, it can seem that the itchy rashes and welts develop when you least expect them. Though it may not ...